|
1
|
Marin JJ, Briz O, Monte MJ, Blazquez AG
and Macias RI: Genetic variants in genes involved in mechanisms of
chemo-resistance to anticancer drugs. Curr Cancer Drug Targets.
12:402–438. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnston PG and Kaye S: Capecitabine: a
novel agent for the treatment of solid tumors. Anticancer Drugs.
12:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin RC II, Scoggins CR, Tomalty D, et
al: Irinotecan drug-eluting beads in the treatment of chemo-naive
unresectable colorectal liver metastasis with concomitant systemic
fluorouracil and oxaliplatin: results of pharmacokinetics and phase
I trial. J Gastrointest Surg. 16:1531–1538. 2012. View Article : Google Scholar
|
|
4
|
Feng QY, Wei Y, Chen JW, et al: Anti-EGFR
and anti-VEGF agents: important targeted therapies of colorectal
liver metastases. World J Gastroenterol. 20:4263–4275. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pinedo HM and Peters GF: Fluorouracil:
biochemistry and pharmacology. J Clin Oncol. 6:1653–1664. 1988.
|
|
6
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sampath D, Rao VA and Plunkett W:
Mechanisms of apoptosis induction by nucleoside analogs. Oncogene.
22:9063–9074. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartek J, Lukas C and Lukas J: Checking on
DNA damage in S phase. Nat Rev Mol Cell Biol. 5:792–804. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aziz K, Nowsheen S, Pantelias G, Iliakis
G, Gorgoulis VG and Georgakilas AG: Targeting DNA damage and
repair: embracing the pharmacological era for successful cancer
therapy. Pharmacol Ther. 133:334–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou BB and Elledge SJ: The DNA damage
response: putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levesque AA and Eastman A: p53-based
cancer therapies: is defective p53 the Achilles heel of the tumor?
Carcinogenesis. 28:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tao ZF and Lin NH: Chk1 inhibitors for
novel cancer treatment. Anticancer Agents Med Chem. 6:377–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma CX, Janetka JW and Piwnica-Worms H:
Death by releasing the breaks: CHK1 inhibitors as cancer
therapeutics. Trends Mol Med. 17:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maugeri-Saccà M, Bartucci M and De Maria
R: Checkpoint kinase 1 inhibitors for potentiating systemic
anticancer therapy. Cancer Treat Rev. 39:525–533. 2013.PubMed/NCBI
|
|
17
|
Sangster-Guity N, Conrad BH, Papadopoulos
N and Bunz F: ATR mediates cisplatin resistance in a p53
genotype-specific manner. Oncogene. 30:2526–2533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Z, Xiao Z, Gu WZ, et al: Selective
Chk1 inhibitors differentially sensitize p53-deficient cancer cells
to cancer therapeutics. Int J Cancer. 119:2784–2794. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiao Z, Xue J, Sowin TJ, Rosenberg SH and
Zhang H: A novel mechanism of checkpoint abrogation conferred by
Chk1 down-regulation. Oncogene. 24:1403–1411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y and Hunter T: Roles of Chk1 in
cell biology and cancer therapy. Int J Cancer. 134:1013–1023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh NP, McCoy MT, Tice RR and Schneider
EL: A simple technique for quantitation of low levels of DNA damage
in individual cells. Exp Cell Res. 175:184–191. 1988. View Article : Google Scholar
|
|
22
|
Lu Y, Morimoto K and Nakayama K: Health
practices and leukocyte DNA damage in Japanese hard-metal workers.
Prev Med. 43:140–144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshikawa R, Kusunoki M, Yanagi H, et al:
Dual antitumor effects of 5-fluorouracil on the cell cycle in
colorectal carcinoma cells: a novel target mechanism concept for
pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029–1037.
2001.
|
|
24
|
Okita N, Minato S, Ohmi E, Tanuma S and
Higami Y: DNA damage-induced CHK1 autophosphorylation at Ser296 is
regulated by an intramolecular mechanism. FEBS Lett. 586:3974–3979.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sriuranpong V, Mutirangura A, Gillespie
JW, et al: Global gene expression profile of nasopharyngeal
carcinoma by laser capture microdissection and complementary DNA
microarrays. Clin Cancer Res. 10:4944–4958. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho SH, Toouli CD, Fujii GH, Crain C and
Parry D: Chk1 is essential for tumor cell viability following
activation of the replication checkpoint. Cell Cycle. 4:131–139.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Madoz-Gúrpide J, Cañamero M, Sanchez L,
Solano J, Alfonso P and Casal JI: A proteomics analysis of cell
signaling alterations in colorectal cancer. Mol Cell Proteomics.
6:2150–2164. 2007.PubMed/NCBI
|
|
28
|
Verlinden L, Vanden Bempt I, Eelen G, et
al: The E2F-regulated gene Chk1 is highly expressed in
triple-negative estrogen receptor/progesterone receptor/HER-2
breast carcinomas. Cancer Res. 67:6574–6581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao H, Yang Z and Li Y: Expression of
checkpoint kinase 1 and polo-like kinase 1 and its
clinicopathological significance in benign and malignant lesions of
the stomach. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 35:1080–1084.
2010.(In Chinese).
|
|
30
|
Hong J, Hu K, Yuan Y, et al: CHK1 targets
spleen tyrosine kinase (L) for proteolysis in hepatocellular
carcinoma. J Clin Invest. 122:2165–2175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu J, Li Y, Wang F, et al: Suppressed
miR-424 expression via upregulation of target gene Chk1 contributes
to the progression of cervical cancer. Oncogene. 32:976–987. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lundgren K, Holm K, Nordenskjöld B, Borg A
and Landberg G: Gene products of chromosome 11q and their
association with CCND1 gene amplification and tamoxifen resistance
in premenopausal breast cancer. Breast Cancer Res. 10:R812008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perego P, Gatti L, Righetti SC, et al:
Development of resistance to a trinuclear platinum complex in
ovarian carcinoma cells. Int J Cancer. 105:617–624. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cavelier C, Didier C, Prade N, et al:
Constitutive activation of the DNA damage signaling pathway in
acute myeloid leukemia with complex karyotype: potential importance
for checkpoint targeting therapy. Cancer Res. 69:8652–8661. 2009.
View Article : Google Scholar
|
|
36
|
Zhang YW, Brognard J, Coughlin C, et al:
The F box protein Fbx6 regulates Chk1 stability and cellular
sensitivity to replication stress. Mol Cell. 35:442–453. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartucci M, Svensson S, Romania P, et al:
Therapeutic targeting of Chk1 in NSCLC stem cells during
chemotherapy. Cell Death Differ. 19:768–778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Ma Z, Xiao Z, et al: Chk1
knockdown confers radiosensitization in prostate cancer stem cells.
Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
|
|
39
|
Brody LC: Treating cancer by targeting a
weakness. N Engl J Med. 353:949–950. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Audeh MW, Carmichael J, Penson RT, et al:
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients
with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a
proof-of-concept trial. Lancet. 376:245–251. 2010. View Article : Google Scholar
|
|
41
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dar AC, Das TK, Shokat KM and Cagan RL:
Chemical genetic discovery of targets and anti-targets for cancer
polypharmacology. Nature. 486:80–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Petitjean A, Mathe E, Kato S, et al:
Impact of mutant p53 functional properties on TP53 mutation
patterns and tumor phenotype: lessons from recent developments in
the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB
and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in
simvastatin induced S-phase cell cycle arrest and apoptosis in
multiple myeloma cells. Eur J Pharmacol. 670:356–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sahu RP, Batra S and Srivastava SK:
Activation of ATM/Chk1 by curcumin causes cell cycle arrest and
apoptosis in human pancreatic cancer cells. Br J Cancer.
100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jazayeri A, Falck J, Lukas C, et al: ATM-
and cell cycle-dependent regulation of ATR in response to DNA
double-strand breaks. Nat Cell Biol. 8:37–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cuadrado M, Martinez-Pastor B, Murga M, et
al: ATM regulates ATR chromatin loading in response to DNA
double-strand breaks. J Exp Med. 203:297–303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eastman A: Cell cycle checkpoints and
their impact on anti-cancer therapeutic strategies. J Cell Biochem.
91:223–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu Q, Guntuku S, Cui XS, et al: Chk1 is
an essential kinase that is regulated by Atr and required for the
G(2)/M DNA damage checkpoint. Genes Dev. 14:1448–1459.
2000.PubMed/NCBI
|
|
50
|
Takai H, Naka K, Okada Y, et al:
Chk2-deficient mice exhibit radioresistance and defective
p53-mediated transcription. EMBO J. 21:5195–5205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bhonde MR, Hanski ML, Magrini R, et al:
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces
apoptosis in colon carcinoma cells through transcriptional
suppression of the Bcl-x(L) protein. Oncogene. 24:148–156. 2005.
View Article : Google Scholar
|
|
52
|
Mitchell C, Park M, Eulitt P, Yang C,
Yacoub A and Dent P: Poly(ADP-ribose) polymerase 1 modulates the
lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol.
78:909–917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tang Y, Dai Y, Grant S and Dent P:
Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol
Ther. 13:379–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
